ARDS News and Press, Aridis Pharmaceuticals Inc. From 11/20/20

Aridis Pharmaceuticals Announces Third Quarter 2020 Results PR Newswire SAN JOSE, Calif., Nov. 20, 2020 SAN JOSE, Calif. , Nov. 20, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and deve...

The following slide deck was published by Aridis Pharmaceuticals, Inc. in conjunction with this event. For further details see: Aridis Pharmaceuticals (ARDS) Investor Presentation - Slideshow

/C O R R E C T I O N -- Aridis Pharmaceuticals, Inc./ PR Newswire SAN JOSE, Calif., Oct. 27, 2020 In the news release, Aridis Pharmaceuticals to Present at the ROTH Capital Partners 2020 MedTech Innovation Forum on a COVID-19 Panel, issued 27-Oct-2020 by Aridis P...

Aridis Pharmaceuticals to Present at the ROTH Capital Partners 2020 MedTech Innovation Forum on a COVID-19 Panel PR Newswire SAN JOSE, Calif., Oct. 27, 2020 SAN JOSE, Calif. , Oct. 27, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopha...

Ultra-thinly traded nano cap Aridis Pharmaceuticals (ARDS) perks up 7% premarket on light volume in reaction to its announcement of preclinical data supporting the potential efficacy of an inhalable formulation of AR-711, a neutralizing monoclonal antibody, for treating COVID-19.In ...

Aridis Pharmaceuticals Reports Positive Preclinical Efficacy Data of a Highly Effective Inhaled Treatment Supporting a Proposed Self-Administered Therapy for COVID-19 Patients PR Newswire SAN JOSE, Calif., Oct. 19, 2020 SAN JOSE, Calif. , Oct. 19, 2020 /PRNew...

Aridis Pharmaceuticals (ARDS) enters agreement with institutional investors for the sale of 1,134,470 shares of common stock at $7.4925 per share, for a gross proceed of $8.5M.In a concurrent private placement, the investors agreed to purchase two series of warrants for an aggregate 567,234 s...

Aridis Pharmaceuticals Announces $8.5 Million Registered Direct Offering Company Enters Into Securities Purchase Agreement with Institutional Investors PR Newswire SAN JOSE, Calif., Oct. 14, 2020 SAN JOSE, Calif. , Oct. 14, 2020 /PRNewswire/ -- Aridis Pha...

Albireo reports positive data from Phase 3 trial Albireo Pharma, Inc. (ALBO) reported positive top-line data from PEDFIC 1 trial for odevixibat. The study met both its primary endpoints. The drug candidate is a highly potent, non-systemic ileal bile acid transport inhibitor. It is being ...

Aridis Pharmaceuticals (NASDAQ: ARDS ) has reached an agreement with the FDA to simplify its AR-501 Phase 2 trial design for the treatment of chronic lung infections associated with cystic fibrosis (CF). More news on: Aridis Pharmaceuticals, Inc., Healthcare stocks news, Read more ...